Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
CFTR
cardiorespiratory polygraphy
cystic fibrosis
elexacaftor/tezacaftor/ivacaftor
modulators
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
09 02 2023
09 02 2023
Historique:
received:
05
12
2022
revised:
17
01
2023
accepted:
06
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators represent targeted therapies directly acting on the CFTR channel. The triple therapy Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) has been demonstrated to improve lung function and quality of life in cystic fibrosis (CF) patients. However, the effects of ELX/TEZ/IVA on sleep-disordered breathing (SDB) and respiratory muscle strength are poorly studied. The aim of this study was to assess the effects of ELX/TEZ/IVA in patients with CF and severe lung disease on cardiorespiratory polygraphy parameters, maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measures. patients with CF aged ≥ 12 who started treatment in a compassionate use program were retrospectively studied through the evaluation of nocturnal cardiorespiratory polygraphy parameters, MIP and MEP; and six-minute walk test (6MWT) at baseline and at months 3, 6, and 12 of treatment. Nine patients (mean age 30.3 ± 6.5 years) with severe CF (mean baseline ppFEV1 34.6 ± 5.1%) were evaluated. A significant improvement in nocturnal oxygenation measured by mean SpO We provide further evidence on the efficacy of the CFTR modulators ELX/TEZ/IVA, adding information about their effect on the respiratory muscles' performance and cardiorespiratory polygraphy parameters in CF patients with severe lung disease.
Sections du résumé
BACKGROUND
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators represent targeted therapies directly acting on the CFTR channel. The triple therapy Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) has been demonstrated to improve lung function and quality of life in cystic fibrosis (CF) patients. However, the effects of ELX/TEZ/IVA on sleep-disordered breathing (SDB) and respiratory muscle strength are poorly studied. The aim of this study was to assess the effects of ELX/TEZ/IVA in patients with CF and severe lung disease on cardiorespiratory polygraphy parameters, maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) measures.
METHODS
patients with CF aged ≥ 12 who started treatment in a compassionate use program were retrospectively studied through the evaluation of nocturnal cardiorespiratory polygraphy parameters, MIP and MEP; and six-minute walk test (6MWT) at baseline and at months 3, 6, and 12 of treatment.
RESULTS
Nine patients (mean age 30.3 ± 6.5 years) with severe CF (mean baseline ppFEV1 34.6 ± 5.1%) were evaluated. A significant improvement in nocturnal oxygenation measured by mean SpO
CONCLUSIONS
We provide further evidence on the efficacy of the CFTR modulators ELX/TEZ/IVA, adding information about their effect on the respiratory muscles' performance and cardiorespiratory polygraphy parameters in CF patients with severe lung disease.
Identifiants
pubmed: 36833376
pii: genes14020449
doi: 10.3390/genes14020449
pmc: PMC9956139
pii:
doi:
Substances chimiques
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
elexacaftor
RRN67GMB0V
ivacaftor
1Y740ILL1Z
tezacaftor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Chest. 1999 May;115(5):1321-8
pubmed: 10334147
Lancet Respir Med. 2022 Mar;10(3):267-277
pubmed: 34942085
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30
pubmed: 19846789
Molecules. 2022 Aug 21;27(16):
pubmed: 36014562
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8
pubmed: 21976485
Science. 1989 Sep 8;245(4922):1066-73
pubmed: 2475911
Respir Care. 2019 Apr;64(4):406-415
pubmed: 30254044
Am J Respir Crit Care Med. 2003 Oct 15;168(8):989-94
pubmed: 12829457
Pediatr Pulmonol. 2012 Nov;47(11):1123-30
pubmed: 22431492
Physiother Res Int. 2018 Oct;23(4):e1720
pubmed: 29943880
J Cyst Fibros. 2015 Sep;14(5):639-45
pubmed: 26005006
Genes (Basel). 2021 Jul 29;12(8):
pubmed: 34440351
Pediatr Pulmonol. 2022 Nov;57(11):2652-2658
pubmed: 35851858
Lancet Respir Med. 2016 Aug;4(8):e37-e38
pubmed: 27377414
Pediatr Pulmonol. 2022 Aug;57(8):1944-1951
pubmed: 33974362
J Cyst Fibros. 2009 Jan;8(1):31-6
pubmed: 18838310
Eur Respir Rev. 2020 Mar 20;29(155):
pubmed: 32198216
Arch Dis Child. 2005 Nov;90(11):1138-43
pubmed: 16243867
Eur Respir J. 2002 Mar;19(3):504-10
pubmed: 11936530
J Clin Sleep Med. 2012 Oct 15;8(5):597-619
pubmed: 23066376
Respir Med. 2018 Apr;137:83-88
pubmed: 29605218
J Mol Diagn. 2013 May;15(3):331-40
pubmed: 23470247
J Cyst Fibros. 2021 Mar;20(2):243-249
pubmed: 32855088
Respiration. 2022;101(8):766-774
pubmed: 35598598
Pharmacol Ther. 2001 Oct;92(1):1-20
pubmed: 11750034
Respir Med. 2013 Dec;107(12):1881-7
pubmed: 24157200
Chest. 1999 Sep;116(3):647-54
pubmed: 10492266
Pediatr Pulmonol. 2019 Apr;54(4):451-456
pubmed: 30575341
Eur Respir J. 2017 Jan 4;49(1):
pubmed: 28052955
Clin Respir J. 2018 Feb;12(2):754-761
pubmed: 27925430
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Lancet. 2019 Nov 23;394(10212):1940-1948
pubmed: 31679946
Rev Port Pneumol (2006). 2016 Jul-Aug;22(4):202-8
pubmed: 27052354
Nat Rev Genet. 2015 Jan;16(1):45-56
pubmed: 25404111
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Genes (Basel). 2020 May 26;11(6):
pubmed: 32466381
Arch Dis Child. 2012 Nov;97(11):960-6
pubmed: 22984185
Pediatr Pulmonol. 2007 Aug;42(8):716-22
pubmed: 17595040
J Cyst Fibros. 2022 Jan;21(1):160-163
pubmed: 33832855
Front Pharmacol. 2020 Feb 21;10:1662
pubmed: 32153386
Sleep Med Rev. 2020 Jun;51:101279
pubmed: 32145647
Breathe (Sheff). 2022 Sep;18(3):220151
pubmed: 36340818
Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73
pubmed: 33600738
Am J Physiol Regul Integr Comp Physiol. 2022 Jun 1;322(6):R551-R561
pubmed: 35411814
Pediatr Pulmonol. 2020 Aug;55(8):1974-1983
pubmed: 32364318
Respir Med. 2020 Apr;164:105906
pubmed: 32217291
J Cyst Fibros. 2017 Nov;16(6):719-726
pubmed: 28479021
Sleep Med. 2020 Oct;74:57-65
pubmed: 32841845
Front Pediatr. 2018 Sep 04;6:244
pubmed: 30234080
J Clin Med. 2022 Feb 16;11(4):
pubmed: 35207295
Chest. 2014 Nov;146(5):1387-1394
pubmed: 25367475
J Cyst Fibros. 2018 Mar;17(2):153-178
pubmed: 29506920
J Cyst Fibros. 2011 Mar;10(2):100-6
pubmed: 21195036
Respir Med. 2019 May;151:96-101
pubmed: 31047123
Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624
pubmed: 12186831
Arch Pediatr Adolesc Med. 2012 Dec;166(12):1165-9
pubmed: 23090511
N Engl J Med. 2017 Nov 23;377(21):2024-2035
pubmed: 29099333
J Bras Pneumol. 2013 Nov-Dec;39(6):667-74
pubmed: 24473760
Mol Genet Genomic Med. 2021 Apr;9(4):e1656
pubmed: 33713579
BMC Pulm Med. 2019 Jun 17;19(1):106
pubmed: 31208380
J Pediatr. 2017 Feb;181S:S4-S15.e1
pubmed: 28129811
Antibiotics (Basel). 2021 Jul 07;10(7):
pubmed: 34356748
N Engl J Med. 2019 Nov 7;381(19):1809-1819
pubmed: 31697873
J Cyst Fibros. 2014 Jul;13(4):403-9
pubmed: 24440181
Respir Med. 2021 Nov-Dec;189:106646
pubmed: 34673344
Am Rev Respir Dis. 1990 Jun;141(6):1506-9
pubmed: 2350092